ArticleCureus2025
Eight-Year Survival Analysis of Patients With Dilated Cardiomyopathy: Does Treatment Era Affect Prognosis?
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Dilated cardiomyopathy (DCM) is a leading cause of heart failure (HF). We retrospectively analyzed long-term survival in DCM and the impact of clinical factors on their prognosis. Methods This was a retrospective analysis of 622 DCM patients (484 men, 138 women). Survival was compared between the 2016-2019 and 2020-2023 cohorts. Results The mean age was similar between cohorts (54 ± 13 vs. 55 ± 13 years). Mean overall survival for the entire cohort was 84.1 ± 1.6 months (95% CI: 81.0-87.4). When analyzed by period, mean survival was 84.1 ± 2.0 months (95% CI: 80.3-87.9) for patients diagnosed between 2016 and 2019 and 53.4 ± 1.1 months (95% CI: 51.2-55.6) for those diagnosed between 2020 and 2023. The difference was not statistically significant (log-rank p = 0.856). The shorter mean survival in the later period reflects the limited follow-up time due to ongoing observation. In the 2020-2023 group, a higher proportion of patients were classified as New York Heart Association (NYHA) III/IV (56% vs. 48%, p = 0.036) and had larger ventricular diameters (left ventricular end-diastolic diameter (LVEDD): 68 ± 8 mm vs. 66 ± 7 mm, p = 0.001; right ventricle (RV): 36 ± 7 mm vs. 34 ± 6 mm, p = 0.001). Treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) did not significantly affect survival. Multivariable analysis identified older age, NYHA class III/IV, chronic kidney disease (CKD) stages 3-5, diabetes, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >3000 ng/L as independent negative predictors, while female sex and overweight status were associated with better survival. Multivariable analysis identified older age, NYHA III/IV, CKD stages 3-5, diabetes, and NT-proBNP >3000 ng/L as independent negative predictors. Female sex and overweight status were associated with improved survival. Conclusions Survival in DCM patients remained stable across time periods, despite a higher-risk profile in recent years, potentially influenced by the COVID-19 pandemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.